Market Cap 1.44B
Revenue (ttm) 49.08M
Net Income (ttm) -109.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -223.15%
Debt to Equity Ratio 0.00
Volume 4,272,700
Avg Vol 4,070,578
Day's Range N/A - N/A
Shares Out 53.24M
Stochastic %K 100%
Beta -0.12
Analysts Sell
Price Target $29.17

Company Profile

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation i...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 999 0075
Fax: 866 553 3269
Address:
200 Crossing Boulevard, Framingham, United States
JuggernautRaider
JuggernautRaider Jun. 21 at 7:52 AM
$TNXP $NUVB $MIST $KALV do you work for free? No? Then… why should I?
3 · Reply
Quantumup
Quantumup Jun. 16 at 1:17 PM
H.C. Wainwright reiterated $PHVS Buy; $60 and said: European Academy of Allergy and Clinical Immunology (EAACI) 2026 reinforced deucrictibant's dual-use hereditary angioedema (HAE) profile across treatment settings. $KALV IONS TAK $BCRX Here's what H.C. Wainwright went on to say: https://x.com/Quantumup1/status/2066872400218575096?s=20
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 16 at 9:23 AM
$FBIO starting to realize we could have made more on the prediction markets by getting Zycubo’s approvsl right and also the sale of the priority review voucher 🤷‍♂️ FBIOP is a drain on Fortress but c’est la vie Lesson learned for $TNXP and others as well if I launch the educational platform on healthcare/ biopharma investing. 🤔 Like $NUVB and $KALV … I called all four approvals over the past 12 months (and avoided other duds). 4️⃣ Lesson learned! Back to work 💪
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 14 at 3:52 PM
$KALV KalVista Pharmaceuticals (NASDAQ: KALV) became a special-case biotech after Chiesi’s $1.9 billion acquisition agreement. This rare disease stock now offers a lesson in how Big Pharma hunts for valuable biotech assets. https://biotechhealthx.com/biotech-news/is-kalvista-pharmaceuticals-kalv-one-of-the-most-overlooked-rare-disease-stocks-right-now/
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 12 at 9:48 AM
$EWTX $IOVA $NRIX $KALV $REPL Small-cap biotech stocks are heating up as investors hunt for FDA catalysts, rare disease breakthroughs, cancer treatments, and Big Pharma buyout potential. These 10 biotech names could be among the most interesting stocks to watch now. https://biotechhealthx.com/biotech-news/top-10-small-cap-biotech-stocks-that-could-surge-100/
1 · Reply
G101SPM
G101SPM Jun. 11 at 12:49 PM
CLASSIC EXAMPLE TO SUPPORT PERFORMANCE OF SPM TAGS $KALV $27.00 / BOOK SELL IN BALNCE OF LONG POSITION AT $27.00 DAC (dollar average cost includes partial SELLS at profit to reduce net cost to $0.89. https://stocktwits.com/search/u/G101SPM?symbol=KALV UPDATE: KalVista Pharmaceuticals: Chiesi Group completes acquisition of KalVista Pharmaceuticals (27.00) As a result of the merger, KalVista became a wholly owned subsidiary of Chiesi and KalVista's common stock ceased trading on the Nasdaq Global Market. Additional details regarding the tender can be found in a form 8-K filed by KalVista today with the Securities and Exchange Commission.
0 · Reply
TwongStocks
TwongStocks Jun. 11 at 12:42 PM
$KALV Chiesi Group Completes Acquisition of KalVista Pharmaceuticals https://www.businesswire.com/news/home/20260610759093/en/Chiesi-Group-Completes-Acquisition-of-KalVista-Pharmaceuticals On June 11, 2026, Chiesi successfully completed its tender offer for all outstanding shares of KalVista common stock for $27.00 per share in cash and accepted for payment all shares validly tendered and not validly withdrawn as of the expiration time of the tender offer, which shares represented approximately 77.8% of KalVista’s outstanding shares. Following completion of the offer, Chiesi completed its acquisition of KalVista through a merger of a wholly owned subsidiary of Chiesi with and into KalVista, in connection with which the outstanding shares of KalVista common stock were cancelled and converted into the right to receive the same $27.00 per share in cash.
0 · Reply
TwongStocks
TwongStocks Jun. 5 at 8:05 PM
$KALV Equity Corporate Actions Alert #2026 - 390 Information Regarding the Merger of KalVista Pharmaceuticals, Inc. (KALV) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-390 The tender offer by Skyline Merger Sub, Inc. a wholly owned subsidiary of Chiesi Farmaceutici S.p.A. to acquire all of the outstanding common stock of KalVista Pharmaceuticals, Inc. (KALV) is scheduled to expire one minute after 11:59 p.m. ET, on June 10, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on June 11, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on June 10, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (June 11th) and will be suspended effective June 12, 2026.
0 · Reply
SuperGreenToday
SuperGreenToday May. 19 at 12:39 AM
$KALV Share Price: $26.75 Contract Selected: Dec 18, 2026 $25 Calls Buy Zone: $1.72 – $2.13 Target Zone: $2.83 – $3.46 Potential Upside: 55% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 17 at 2:17 AM
$KALV filed their 14D9 with the SEC last Wednesday. The filing includes, among other things, the financial projection provided Chiesi that of course included an Eckterly revenue forecast. The attachment compares the revenue forecast prepared by KALV mgmt/BOD to analyst consensus revenue estimates per Seeking Alpha. KALV's mgmt/BOD prepared 5 & 10-year revenue forecast was roughly 10% lower than analysts. We recall $SLNO mgmt/BOD prepared revenue forecast was lower but it's our experience the variance is usually the other way around. This also means the revenue multiples paid were higher. The SLNO 5-year multiple was 0.70 where KALV's was 1.02X. KALV projected a gross margin of 87.4% over the first 10 years of Eckterly's launch. As always, this is not investment advice. We're merely sharing analysis. $XBI $IBB
1 · Reply
Latest News on KALV
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

Jun 11, 2026, 8:41 AM EDT - 13 days ago

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals


KalVista Pharmaceuticals Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 5 weeks ago

KalVista Pharmaceuticals Quarterly report: Q1 2026


Italian drugmaker Chiesi to buy KalVista for $1.9 billion

Apr 29, 2026, 7:53 AM EDT - 2 months ago

Italian drugmaker Chiesi to buy KalVista for $1.9 billion


KalVista Pharmaceuticals Transcript: Transition period

Mar 25, 2026, 8:30 AM EDT - 3 months ago

KalVista Pharmaceuticals Transcript: Transition period


KalVista Pharmaceuticals Earnings release: Transition period

Mar 25, 2026, 8:30 AM EDT - 3 months ago

KalVista Pharmaceuticals Earnings release: Transition period


KalVista Pharmaceuticals Slides: Corporate presentation

Mar 24, 2026, 7:00 AM EDT - 3 months ago

KalVista Pharmaceuticals Slides: Corporate presentation


KalVista Pharmaceuticals Slides: Corporate Presentation

Jan 9, 2026, 7:00 AM EST - 5 months ago

KalVista Pharmaceuticals Slides: Corporate Presentation


KalVista Pharmaceuticals Earnings Call Transcript: Q3 2026

Nov 11, 2025, 8:30 AM EST - 8 months ago

KalVista Pharmaceuticals Earnings Call Transcript: Q3 2026


KalVista Pharmaceuticals Quarterly report: Q3 2026

Nov 11, 2025, 8:30 AM EST - 8 months ago

KalVista Pharmaceuticals Quarterly report: Q3 2026


KalVista Pharmaceuticals Earnings release: Q3 2026

Nov 11, 2025, 8:30 AM EST - 8 months ago

KalVista Pharmaceuticals Earnings release: Q3 2026


KalVista Pharmaceuticals Slides: Investor Presentation

Nov 9, 2025, 6:00 PM EST - 8 months ago

KalVista Pharmaceuticals Slides: Investor Presentation


KalVista Pharmaceuticals Earnings Call Transcript: Q1 2026

Sep 11, 2025, 8:30 AM EDT - 10 months ago

KalVista Pharmaceuticals Earnings Call Transcript: Q1 2026


KalVista Pharmaceuticals Quarterly report: Q1 2026

Sep 11, 2025, 8:30 AM EDT - 10 months ago

KalVista Pharmaceuticals Quarterly report: Q1 2026


KalVista Pharmaceuticals Earnings release: Q1 2026

Sep 11, 2025, 8:30 AM EDT - 10 months ago

KalVista Pharmaceuticals Earnings release: Q1 2026


KalVista Pharmaceuticals Proxy statement: Proxy Filing

Aug 21, 2025, 8:00 AM EDT - 10 months ago

KalVista Pharmaceuticals Proxy statement: Proxy Filing


KalVista Pharmaceuticals Proxy statement: Proxy Filing

Aug 21, 2025, 8:00 AM EDT - 10 months ago

KalVista Pharmaceuticals Proxy statement: Proxy Filing


Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

Aug 11, 2025, 4:05 PM EDT - 11 months ago

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

MGX


KalVista Pharmaceuticals Annual report: Q4 2025

Jul 10, 2025, 7:00 AM EDT - 1 year ago

KalVista Pharmaceuticals Annual report: Q4 2025


KalVista Pharmaceuticals Earnings release: Q4 2025

Jul 10, 2025, 7:00 AM EDT - 1 year ago

KalVista Pharmaceuticals Earnings release: Q4 2025


KalVista Pharmaceuticals Transcript: FDA Announcement

Jul 7, 2025, 8:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Transcript: FDA Announcement


KalVista Pharmaceuticals Press release: FDA Announcement

Jul 7, 2025, 8:30 AM EDT - 1 year ago

KalVista Pharmaceuticals Press release: FDA Announcement


US FDA approves KalVista Pharma's swelling disorder drug

Jul 7, 2025, 6:37 AM EDT - 1 year ago

US FDA approves KalVista Pharma's swelling disorder drug


KalVista Pharmaceuticals Slides: Corporate Presentation

May 1, 2025, 7:00 AM EDT - 1 year ago

KalVista Pharmaceuticals Slides: Corporate Presentation


JuggernautRaider
JuggernautRaider Jun. 21 at 7:52 AM
$TNXP $NUVB $MIST $KALV do you work for free? No? Then… why should I?
3 · Reply
Quantumup
Quantumup Jun. 16 at 1:17 PM
H.C. Wainwright reiterated $PHVS Buy; $60 and said: European Academy of Allergy and Clinical Immunology (EAACI) 2026 reinforced deucrictibant's dual-use hereditary angioedema (HAE) profile across treatment settings. $KALV IONS TAK $BCRX Here's what H.C. Wainwright went on to say: https://x.com/Quantumup1/status/2066872400218575096?s=20
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 16 at 9:23 AM
$FBIO starting to realize we could have made more on the prediction markets by getting Zycubo’s approvsl right and also the sale of the priority review voucher 🤷‍♂️ FBIOP is a drain on Fortress but c’est la vie Lesson learned for $TNXP and others as well if I launch the educational platform on healthcare/ biopharma investing. 🤔 Like $NUVB and $KALV … I called all four approvals over the past 12 months (and avoided other duds). 4️⃣ Lesson learned! Back to work 💪
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 14 at 3:52 PM
$KALV KalVista Pharmaceuticals (NASDAQ: KALV) became a special-case biotech after Chiesi’s $1.9 billion acquisition agreement. This rare disease stock now offers a lesson in how Big Pharma hunts for valuable biotech assets. https://biotechhealthx.com/biotech-news/is-kalvista-pharmaceuticals-kalv-one-of-the-most-overlooked-rare-disease-stocks-right-now/
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 12 at 9:48 AM
$EWTX $IOVA $NRIX $KALV $REPL Small-cap biotech stocks are heating up as investors hunt for FDA catalysts, rare disease breakthroughs, cancer treatments, and Big Pharma buyout potential. These 10 biotech names could be among the most interesting stocks to watch now. https://biotechhealthx.com/biotech-news/top-10-small-cap-biotech-stocks-that-could-surge-100/
1 · Reply
G101SPM
G101SPM Jun. 11 at 12:49 PM
CLASSIC EXAMPLE TO SUPPORT PERFORMANCE OF SPM TAGS $KALV $27.00 / BOOK SELL IN BALNCE OF LONG POSITION AT $27.00 DAC (dollar average cost includes partial SELLS at profit to reduce net cost to $0.89. https://stocktwits.com/search/u/G101SPM?symbol=KALV UPDATE: KalVista Pharmaceuticals: Chiesi Group completes acquisition of KalVista Pharmaceuticals (27.00) As a result of the merger, KalVista became a wholly owned subsidiary of Chiesi and KalVista's common stock ceased trading on the Nasdaq Global Market. Additional details regarding the tender can be found in a form 8-K filed by KalVista today with the Securities and Exchange Commission.
0 · Reply
TwongStocks
TwongStocks Jun. 11 at 12:42 PM
$KALV Chiesi Group Completes Acquisition of KalVista Pharmaceuticals https://www.businesswire.com/news/home/20260610759093/en/Chiesi-Group-Completes-Acquisition-of-KalVista-Pharmaceuticals On June 11, 2026, Chiesi successfully completed its tender offer for all outstanding shares of KalVista common stock for $27.00 per share in cash and accepted for payment all shares validly tendered and not validly withdrawn as of the expiration time of the tender offer, which shares represented approximately 77.8% of KalVista’s outstanding shares. Following completion of the offer, Chiesi completed its acquisition of KalVista through a merger of a wholly owned subsidiary of Chiesi with and into KalVista, in connection with which the outstanding shares of KalVista common stock were cancelled and converted into the right to receive the same $27.00 per share in cash.
0 · Reply
TwongStocks
TwongStocks Jun. 5 at 8:05 PM
$KALV Equity Corporate Actions Alert #2026 - 390 Information Regarding the Merger of KalVista Pharmaceuticals, Inc. (KALV) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-390 The tender offer by Skyline Merger Sub, Inc. a wholly owned subsidiary of Chiesi Farmaceutici S.p.A. to acquire all of the outstanding common stock of KalVista Pharmaceuticals, Inc. (KALV) is scheduled to expire one minute after 11:59 p.m. ET, on June 10, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on June 11, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on June 10, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (June 11th) and will be suspended effective June 12, 2026.
0 · Reply
SuperGreenToday
SuperGreenToday May. 19 at 12:39 AM
$KALV Share Price: $26.75 Contract Selected: Dec 18, 2026 $25 Calls Buy Zone: $1.72 – $2.13 Target Zone: $2.83 – $3.46 Potential Upside: 55% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 17 at 2:17 AM
$KALV filed their 14D9 with the SEC last Wednesday. The filing includes, among other things, the financial projection provided Chiesi that of course included an Eckterly revenue forecast. The attachment compares the revenue forecast prepared by KALV mgmt/BOD to analyst consensus revenue estimates per Seeking Alpha. KALV's mgmt/BOD prepared 5 & 10-year revenue forecast was roughly 10% lower than analysts. We recall $SLNO mgmt/BOD prepared revenue forecast was lower but it's our experience the variance is usually the other way around. This also means the revenue multiples paid were higher. The SLNO 5-year multiple was 0.70 where KALV's was 1.02X. KALV projected a gross margin of 87.4% over the first 10 years of Eckterly's launch. As always, this is not investment advice. We're merely sharing analysis. $XBI $IBB
1 · Reply
TwongStocks
TwongStocks May. 13 at 11:28 AM
$KALV Tender offer has officially commenced https://www.sec.gov/Archives/edgar/data/1348911/000114036126020935/ny20071872x1_sctot.htm • Expires 1 minute after 11:59pm ET on June 10, unless extended. • At least 50% of outstanding shares must be tendered for deal to close. • Tender offer is $27.00 per share Full tender offer: https://www.sec.gov/Archives/edgar/data/1348911/000114036126020935/ny20071872x1_exa1a.htm
0 · Reply
Quantumup
Quantumup May. 13 at 11:12 AM
Citizens⬇️ $PHVS's PT to $74 (was $75), reiterated at a Market Outperform, and said: The Phase 3 CHAPTER-3 readout coming in 3Q26 is the next key catalyst for shares. $KALV $BCRX IONS TAK Citizens added—In Phase 2, deucrictibant showed an ~85% attack reduction, which is in line with injectable prophylactics. If confirmed in Phase 3, deucrictibant XR could emerge as a differentiated oral option in an increasingly competitive HAE landscape. Meanwhile, the acute franchise is de-risked with robust RAPIDe-3 data supporting an NDA submission this quarter. We assign deucrictibant a POS of 90% for HAE treatment and 70% in HAE prophylaxis, with peak sales of~$950M and ~ $1.6B, respectively.
1 · Reply
TwongStocks
TwongStocks May. 12 at 7:45 PM
$KALV Still waiting on Chiesi to commence the tender offer. Per the 8-K, Chiesi has to initiate the tender offer within 10 business days of the merger agreement. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001348911/000114036126017656/ef20071670_8k.htm "The Merger Agreement provides that Purchaser will commence the Offer no later than 10 business days after the date of the Merger Agreement." Merger agreement was signed Apr 29. If my count is right, ten business days is May 13. Cheisi needs to commence the tender offer by tomorrow.
0 · Reply
Pukkaa56
Pukkaa56 May. 11 at 6:47 AM
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 7 at 6:03 PM
$CPRX M&A valuation as multiples of Year 4 (FY29), 5-year & 10-year revenue estimates versus peer commercial-stage biopharma M&A exits. Peer multiples are calculated using the revenue forecasts prepared by the management/BOD of the acquiree. $KALV & $APLS also use analyst consensus. NOTE CPRX is being acquired at one of the highest 10-year multiples (very likely because CPRX is a much more mature commercial-stage bio versus most of the peers). We're merely sharing our analysis. This is not investment advice. We cannot think of any peer like CPRX (that sold multiple therapies) except for $XERS which has patent life considerations $XBI
4 · Reply
JuggernautRaider
JuggernautRaider May. 4 at 2:11 PM
$SNDX looking juicy for a buyout! I called $KALV and I’m calling Syndax too - not invested currently but may buy dips. GLB ☘️ 🐂
2 · Reply
BearTamerTrading
BearTamerTrading May. 1 at 5:52 PM
$KALV Another Potential Rocket rises to the occasion again ! Congratulations to all members who had access a week in advance one month ago before the public. As always thank you for your trust. I will continue to deliver tremendous value and ROI for just 49.99 a month. I Don’t Miss ! https://youtu.be/ajTV9H8J8ew?si=RsseynwHmvBWjUQ9
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 1 at 1:47 AM
$KALV 's $1.9B M&A enterprise value = 0.93X 5-year analyst consensus & 0.34X 10-year consensus. This appears right down the middle v. peer comm'l-stage M&A exits. The attached table calculates KALV's multiples using analyst consensus where the 11 peers use revenue forecasts prepared by the acquiree's mgnt/BOD. $SNDX has a new analyst providing revenue forecasts, which are now meaningfully higher than last week. SNDX's forecasts are now so high we don't believe they are credible but WTF do we know. We'll wait until analysts swallow today's update before reposting SNDX multiples. All the same, at $20/share SNDX's risk v reward profile is now quite compelling if analyst estimates are credible. SNDX $58MM in Q126 R&D or $200MM+/year? Let's hope there's a return SNDX 5-year consensus FY26-30 now = $3.94B per Seeking Alpha. Put a 0.90 or a 1.0X like KALV? Higher/lower? $ACAD $TARS $ARDX trade @ multiples meaningfully lower than peers (again if analyst estimates are credible). Much more to come.
4 · Reply
Vwill33
Vwill33 May. 1 at 12:45 AM
$KALV anyone looking into NUVB?
0 · Reply
RainyDayFund
RainyDayFund Apr. 30 at 6:21 PM
$KALV So we wait until deal closes and they pay us $27 per share?
1 · Reply
IN0V8
IN0V8 Apr. 30 at 2:23 PM
$KALV Jonestrading cuts to hold rating Leerink Partners cuts to market perform from outperform Leerink Partners raises target to $27 from $22
0 · Reply
topstockalerts
topstockalerts Apr. 30 at 2:18 AM
Top Gainers PT2 $SIMO $RPGL $KALV $FCEL $JLHL
0 · Reply